Stockscreener 앱 받기
7.64
0.52%
-0.04
시간 외 거래:
7.12
-0.52
-6.81%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals Advances Clinical Trials for Soquelitinib - TipRanks
Corvus: Q3 Earnings Snapshot - Chron
Corvus Pharmaceuticals Narrows Losses And Gains Wall Street Support - Finimize
Earnings call transcript: Corvus Pharmaceuticals Q3 2025 narrows loss, stock dips - Investing.com
Corvus Pharma Q3 net loss narrows; R&D expenses rise - MarketScreener
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results - The Manila Times
Corvus Pharmaceuticals (NASDAQ: CRVS) completes AD Phase 1 cohort; PTCL Phase 3 enrolling - Stock Titan
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025Trade Volume Report & Fast Momentum Stock Entry Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTake Profit & Risk Controlled Stock Pick Alerts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockExit Point & Fast Gaining Stock Strategy Reports - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
Corvus Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Real time social sentiment graph for Corvus Pharmaceuticals Inc.2025 Performance Recap & Entry Point Strategy Guides - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackRate Hike & Safe Capital Growth Trade Ideas - newser.com
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com
What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Corvus Pharmaceuticals, Inc. (CRVS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Corvus Pharmaceuticals, Inc. (CRVS) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Corvus Pharmaceuticals Inc. stock momentum explained2025 Analyst Calls & Precise Buy Zone Tips - newser.com
ETFs Investing in Corvus Pharmaceuticals, Inc. Stocks - TradingView
Will Corvus Pharmaceuticals Inc. stock benefit from green energy trendsEarnings Risk Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to host Nov. 4 webcast for financial results update - Stock Titan
1.45%
0.86%
자본화:
|
볼륨(24시간):